Is There a Generic Ozempic? No — And Here's What That Actually Costs You

Disclosure: Some links on this page are affiliate links. If you use them, we may earn a commission at no extra cost to you. It does not change our FDA findings, our sources, or our conclusions. Official manufacturer programs appear on this page before any affiliate option, because on this question they are usually the cheaper answer.

U.S. FDA STATUS · LAST VERIFIED AUGUST 4, 2026

This page is information, not medical advice. Whether a medication fits your situation is a conversation for a licensed clinician or pharmacist.

Is there a generic Ozempic? No. As of August 4, 2026, no generic Ozempic can be legally marketed or sold in the United States. Apotex holds tentative FDA approval for a semaglutide injection, but tentative approval does not permit sale. Compounded semaglutide is not generic Ozempic, and Canada's approved generics do not have U.S. approval. ^{1, 2, 17}

Here's the part almost nobody tells you: official NovoCare self-pay prices for branded Ozempic now run from $149 for a 30-day tablet supply to $499 for a 28-day pen supply, depending on the form and dose. Eligible new pen patients can pay $199 for each of their first two low-dose 28-day fills. None of that is a generic. It is simply the current price of the FDA-approved brand through the manufacturer's program. ⁸

We'll show you the price ladder in a minute, because it changes the decision.

Three things change your next step:

• You have commercial insurance that covers Ozempic for an FDA-approved use. The manufacturer savings offer can reduce an eligible one-, two-, or three-month prescription to as little as $25, subject to maximum savings of $100 per month and activation valid for up to 48 months under the current terms. ⁸
• You want semaglutide for weight loss. Ozempic is not FDA-approved for chronic weight management. Wegovy is the semaglutide product approved for that purpose, and its current tablet self-pay pricing starts at $149 a month. Jump to that section. ^{30, 31}
• You have Medicare or another government prescription plan. The commercial savings card excludes government-program beneficiaries. Your real paths are plan coverage, Extra Help where eligible, the Medicare Prescription Payment Plan, or a separate self-pay purchase that does not count toward your deductible or out-of-pocket limit. Jump to the cost section. ^{8, 9, 33, 32}

This page is for you if:

• You live in the United States and got quoted a price that made you walk away
• You saw a headline about generic Ozempic launching and want to know whether it applies to you
• A website offered you something it called “generic Ozempic” and you want to know what it actually is
• Your insurance denied it, your deductible reset, or your price suddenly jumped

This page is not for you if:

• You're shopping in Canada or another country — the answer there is genuinely different, and this page does not cover foreign pharmacy rules
• You want somewhere to buy semaglutide without a prescription. We don't cover that, and you shouldn't want us to
• You need dosing or switching advice. That's your prescriber's job, not ours

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

The fast version: what you found vs. what it actually is

Sources and verification dates for every row are in the full status board below.

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred form (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose.

Jump to what you came for

1. Is there a generic Ozempic right now?
2. Isn't semaglutide the generic name?
3. How to verify any “generic Ozempic” claim
4. Is compounded semaglutide a generic?
5. Is counterfeit Ozempic circulating in the U.S.?
6. Why Canada has generics and the U.S. does not
7. What Ozempic actually costs today
8. When a U.S. generic could arrive
9. Whether waiting makes financial sense
10. What changes when your goal is weight loss
11. Which FDA-approved generic GLP-1s already exist
12. What to ask your pharmacist or prescriber
13. What we actually verified
14. Frequently asked questions

Is there a generic Ozempic available in the U.S. right now?

No generic Ozempic can be marketed or sold in the United States as of August 4, 2026. Apotex has the first U.S. tentative approval for a generic semaglutide injection that references Ozempic, but tentative approval is not final approval and does not permit U.S. sale. The Ozempic pens and tablets available now are branded Novo Nordisk products. ^{1, 2, 6}

Let's slow down on “tentative approval,” because this is where the headlines go sideways.

On April 10, 2026, Apotex — working with Orbicular Pharmaceutical Technologies — announced that its abbreviated new drug application for semaglutide injection had received the first U.S. tentative approval for a generic version of Ozempic. That's a real milestone. It means the application otherwise met the requirements for approval at that stage of FDA review. ^{1, 2}

But tentative approval is not permission to sell. The FDA is blunt about this: a tentatively approved product cannot be marketed in the United States until it receives final approval. It's a runner who passed the checks and reached the line, but the race has not started. ²

The starting gun is final approval. Patents and exclusivities can keep it from firing, but a date in a patent table is not the same thing as a launch date.

The detail almost nobody catches: it's the injection, not the pill

Here's the detail that changes the answer.

Ozempic now comes in two forms: the injection pen you've probably seen and Ozempic tablets, which became available in the United States on May 4, 2026, in 1.5 mg, 4 mg, and 9 mg strengths. ^{7, 6}

Apotex's tentative approval covers semaglutide injection. It does not create a generic Ozempic tablet. ¹

This matters more than it sounds. A website claiming to sell “generic Ozempic pills” is not describing any finally or tentatively approved U.S. generic product we could verify as of August 4, 2026. Before you assume a headline applies to you, check which product and dosage form it is actually talking about.

The RX Index Generic Ozempic Status Board

Version 1.0 · Last verified: August 4, 2026

Every major category of product an American may encounter under the word “generic,” and what each one actually is.

The status board combines FDA approval rules, current Ozempic labels, Apotex's announcement, FDA compounding guidance, Health Canada decisions, counterfeit alerts, and FDA first-generic records in one product-by-form-by-country view. ^{3, 1, 5, 12, 17, 16, 21, 22, 23}

You are not missing a secret generic. There isn't one hiding behind a login or a coupon code. That's the good news, weirdly — because it means the legitimate lower-cost option you're looking for is something else, and several of those options already exist.

Not sure which path fits your situation?

There is no U.S. generic, but there are four legitimate ways to reduce what you pay: plan coverage and an eligible savings offer, manufacturer self-pay pricing, patient assistance for qualifying uninsured patients, or a different FDA-approved treatment path chosen with a clinician.

→ Use Find My GLP-1 Path

Free. About two minutes.

Wait — isn't semaglutide the generic name for Ozempic?

Semaglutide is the nonproprietary name of the drug ingredient, not proof that a finished product is an FDA-approved generic Ozempic. Ozempic, Wegovy, and Rybelsus are brand products that contain semaglutide. Seeing “semaglutide” on a checkout page tells you the claimed ingredient; it does not tell you the manufacturer, dosage form, approval status, or dispensing source. ^{5, 6}

This trips up smart people constantly. It's not your fault — the words genuinely overlap.

The five details that matter more than the word “semaglutide”

When you're looking at a product page, these five things tell you what you're actually looking at:

1. Manufacturer — who made the finished product
2. Dosage form — injection, pen, vial, or tablet
3. Strength — the exact milligram strength and concentration where relevant
4. FDA status — brand approved, finally approved generic, tentatively approved, compounded, or unapproved
5. Dispensing source — the name and state of the licensed pharmacy or the registered outsourcing facility

If a seller cannot give you all five, you do not have enough information to say yes.

The four questions every “generic” headline should have to answer

We use this internally, and we think you should steal it:

Which product? Which form? Which country? Which approval status?

Run any generic Ozempic headline through those four questions and most confusion disappears in about ten seconds. “Generic Ozempic approved!” Which product — injection or tablet? Which country — the United States or Canada? Which status — tentative or final?

Try it on the next one you see.

How can you verify a “generic Ozempic” claim yourself?

Do not rely on the Orange Book alone. FDA excludes tentatively approved products from the Orange Book because they are not approved drug products, while monthly tentative-approval information appears separately through Drugs@FDA. A complete check therefore requires the tentative-approval report, the Orange Book, the exact dosage form, and evidence that a finally approved product has actually launched. ^{3, 4}

This is the most useful thing on this page, and it's a correction we're making to our own earlier work.

A lot of guides — ours included, in an older article we're updating — tell readers to “check the Orange Book” to see whether a generic exists. That advice is incomplete. FDA's Orange Book preface says tentatively approved products are excluded because they are not approved drug products; separate monthly reports identify tentative approvals. ³

So if you only check the Orange Book, you will not see Apotex's tentative product. That does not mean FDA has never reviewed the application. It means you checked the final-approval database for a product that has not reached final approval.

The RX Index Two-Check Rule

Check 1 — Is it tentatively approved? Open Drugs@FDA's monthly drug-approval reports and select Tentative Approvals by Month. This is where an application that has passed the tentative stage but cannot be marketed appears.

Check 2 — Is it finally approved? Now search the Orange Book for Ozempic and the proposed generic's applicant, dosage form, route, and strength. A final approval should appear in the approved-product record; tentative approvals do not. ^{4, 3}

Check 3 — Confirm the dosage form. Read the approval letter, applicant announcement, or current FDA label. An approval for semaglutide injection is not approval for an Ozempic tablet.

Check 4 — Confirm commercial availability. Final approval and a product being stocked are separate events. FDA itself warns that an approval date does not always mean a generic is commercially available that day. ²⁵

Four checks. Maybe five minutes. And now you never have to take a sales page's word for it again.

The six-question “Is This Actually Generic Ozempic?” checker

Use this before you pay. It is intentionally on the page instead of hidden behind a form.

Your result should land in one of seven buckets: branded Ozempic, tentatively approved injection, compounded product, Canada-only or other foreign authorization, a different generic GLP-1, unverified product, or counterfeit red flag.

It will not tell you whether a medication is right for you. That's your clinician's call. It will tell you whether the words on the offer match its regulatory category.

Classified what you found, but still not sure which treatment path fits?

→ Get your personalized answer with Find My GLP-1 Path

Is compounded semaglutide the same as generic Ozempic?

No. Compounded semaglutide is not an FDA-approved generic and the finished compounded drug does not undergo FDA premarket review for safety, effectiveness, or quality. FDA says a compounded drug may be appropriate when a patient's medical need cannot be met by an approved drug, but marketers cannot describe non-FDA-approved compounded GLP-1 products as generic, the same as an approved drug, made with the same active ingredient, or clinically proven. ^{12, 11}

We want to be careful and fair here, because compounding is a legitimate practice with a real purpose. It is also the category where the most money gets lost on this question.

Under section 503A, a state-licensed pharmacy or physician generally compounds for an identified patient based on a prescription and faces restrictions on making products that are essentially copies of commercially available drugs regularly or in inordinate amounts. Under section 503B, a registered outsourcing facility can operate under a different framework, but its use of bulk drug substances is restricted to substances on the 503B bulks list or drugs on FDA's shortage list at the relevant time. Neither route creates a generic approval. ¹³

What sellers are not allowed to tell you

FDA has been specific about promotional claims for non-FDA-approved compounded GLP-1 products. A marketer cannot claim that its compounded product is:

• Generic Ozempic
• The same as Ozempic
• Made with the same active ingredient as the FDA-approved drug
• Clinically proven to produce patient results

If you see any of those four claims attached to a compounded product, that is your signal to slow down — not to buy faster. ¹¹

What changed, and where the rules stand now

• February 21, 2025: FDA declared the semaglutide injection shortage resolved. The shortage-based enforcement periods later ended for 503A compounders and 503B outsourcing facilities. ¹³
• April 1, 2026 clarification: FDA said semaglutide did not appear on the 503B bulks list or the shortage list and restated the conditions that 503A and 503B compounders must meet. ¹³
• April 30, 2026 proposal: FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list after finding no clinical need for outsourcing facilities to compound them from bulk substances. ¹⁴
• As of August 4, 2026: FDA's current compounding-policy index still lists that April action as a proposal, not a final rule or final determination. ¹⁵

Patient-specific compounding has not simply become illegal. But “patient-specific” is not a magic label that turns mass-market copies into generics. The exact prescription, product difference, pharmacy, facility status, and statutory conditions matter.

Red flags before you pay

FDA's current warnings give you a practical list:

• No licensed clinician actually reviewed your intake
• No prescription is required
• Nobody is available to answer questions after delivery
• The pharmacy name or address cannot be verified
• The label names a pharmacy that says it did not make the product
• The product is labeled “research use only” or “not for human consumption” but comes with consumer dosing instructions
• The product contains semaglutide sodium or semaglutide acetate; FDA says those salt forms are different active ingredients and it is not aware of a lawful basis for their use in compounding
• The concentration or units make the dose easy to misread, especially in a multi-dose vial ¹²

One more set of numbers is worth sitting with. As of May 31, 2026, FDA had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. FDA says the reports are likely undercounted, causation cannot always be determined, and many events resemble known reactions to approved products. It has also received dosing-error reports, some requiring hospitalization. ¹²

We're not putting a provider link in this section, and that's deliberate. We work with GLP-1 providers, including some that offer compounded products. But putting a “buy compounded semaglutide” button on a page titled Is There a Generic Ozempic? would create exactly the blur FDA is policing. So we're not doing it.

A compounded medication may still be a legitimate patient-specific path when a licensed prescriber determines an approved drug cannot meet that patient's medical need and the applicable legal conditions are satisfied. It still is not generic Ozempic. Read our compounded GLP-1 rules guide before you compare offers.

Is counterfeit Ozempic circulating in the United States?

Yes. FDA's current Ozempic counterfeit alert combines three U.S. warnings from December 2023, April 2025, and December 2025. The newest counterfeit batch used PAR1229, which is also an authentic lot number, so a matching lot number alone cannot prove that a pen is genuine. FDA tells patients to use a valid prescription, a state-licensed pharmacy, and the visual details in its alerts. ¹⁶

We assembled this table from FDA's three alert updates because the pattern matters more than any one warning.

The practical lesson is simple: do not use a lot number as your only authenticity check. At least one counterfeit run used an authentic lot number, and the April 2025 warning required a specific lot-and-serial combination. ¹⁶

The reliable protection is boring and it works: a valid prescription, a state-licensed U.S. pharmacy, and a careful look at the product before you use it.

If you received a PAR1229 pen through the Novo Nordisk Patient Assistance Program, FDA says that product is authentic. The counterfeit warning turns on the label layout and supply-chain source, not the lot number by itself. ¹⁶

Why does Canada have generic Ozempic when the U.S. doesn't?

Health Canada authorized Dr. Reddy's generic semaglutide injection referencing Ozempic on April 28, 2026, and a second generic from Apotex on May 1, 2026. Both decisions are Canadian authorizations. They do not create final FDA approval, U.S. pharmacy availability, U.S. therapeutic-equivalence status, or make a generic Ozempic product available through a U.S. pharmacy. ^{17, 18}

This is where a lot of the 2026 confusion came from, and honestly the headlines were not necessarily wrong — they were just about somewhere else.

Drug approvals are country-specific. Which product? Which form? Which country? Which approval status? That four-question rule is doing real work here.

What about websites selling Canadian “generic Ozempic” to Americans?

You will find them. Some use the names of real manufacturers because those companies do have real authorizations in Canada.

That does not settle U.S. legality or product quality. FDA says personal importation of unapproved drugs is illegal in most circumstances and that it cannot ensure the safety or effectiveness of medicines bought from foreign online sources. Narrow enforcement-discretion situations exist, but they are not a normal consumer pathway to a cheaper Ozempic prescription. ¹⁹

We're not going to lecture you about it. We'll give you the decision that matters: before taking on foreign-source, import, and supply-chain risk, compare the official U.S. prices you can verify today.

What is the cheapest legitimate way to get Ozempic without insurance?

The lowest current official U.S. self-pay price is $149 for a 30-day supply of the 1.5 mg Ozempic tablet, which is the starter dose. Ongoing tablet doses cost $199 for 4 mg or $299 for 9 mg; standard pen pricing is $349 for 0.25, 0.5, or 1 mg and $499 for 2 mg. Eligible new pen patients can pay $199 for each of their first two 0.25 or 0.5 mg fills through December 31, 2026. ⁸

The price you were quoted may still be real. It may simply not be the lowest official path available to you.

The Ozempic price ladder — verified August 4, 2026

The savings-offer, self-pay, and PAP terms above come from current NovoCare program pages and terms. Self-pay purchases are processed outside insurance, cannot be submitted for reimbursement, and do not count toward a deductible or true out-of-pocket limit. ^{8, 9}

The price detail that prevents an expensive mistake

The $149 Ozempic tablet is the 1.5 mg starter dose. The FDA label says that dose is used for initiation and is not effective for glycemic control. The ongoing tablet doses are 4 mg and 9 mg, currently priced at $199 and $299. Do not compare the starter price with another program's ongoing-dose price as though they buy the same month of treatment. ^{6, 8}

The list-price page has an internal mismatch — so we are not using it for savings percentages

NovoCare's current Ozempic list-price page displays $1,027.51 for every pen and tablet presentation in its current product list, but the same page also repeats $997.58 lower down for the same products. Because the manufacturer's own page is internally inconsistent, we are not using either figure to claim a precise percentage discount. ¹⁰

The decision-safe numbers are the current program prices in the table above: $149, $199, and $299 for the tablet strengths; $349 or $499 for standard pen fills; and $199 for the first two eligible low-dose pen fills. Those figures come from the current offer terms, not from our estimate. ⁸

The original price you see on an invoice, coupon page, or pharmacy screen is not enough to tell you what you should pay. Compare the exact form, dose, eligibility, and what happens after any introductory fill.

Before we point you anywhere, here's the flaw

Ro is not cheaper than going straight to NovoCare when you already have a prescriber and already know you are paying cash. Ro says its medication prices match NovoCare, LillyDirect, and TrumpRx, then adds a Ro Body membership: $39 for the first month, $149 on the ongoing monthly plan, or as low as $74 a month with an annual plan paid upfront. Medication is billed separately. ²⁶

If you already have a clinician willing to prescribe the appropriate Ozempic product and you know insurance will not cover it, use NovoCare's official self-pay path and skip a membership you do not need.

Here's what the Ro trade actually buys you. NovoCare is a pharmacy path; it does not replace a clinical program. Ro includes clinical evaluation and ongoing support, and its insurance concierge can check coverage and submit prior-authorization paperwork when required. Ro's free public coverage checker currently reports coverage for Ozempic pen, Wegovy pen, and Zepbound pen — not every oral product on Ro's formulary. ^{27, 28, 29}

That distinction is the whole decision:

• Existing prescriber + known cash-pay decision: go direct to NovoCare
• Uncertain Ozempic pen coverage + need a prescriber and prior-authorization support: Ro may earn its membership fee
• Ozempic tablet-specific coverage question: check your plan directly or use your existing prescriber and pharmacy, because Ro's public checker does not list the tablet

Does the second situation sound like yours?

→ Check your Ozempic pen coverage with Ro (sponsored affiliate link; opens in a new tab)

The coverage report is free. Joining Ro Body costs $39 for the first month if you are eligible for treatment; medication is separate. Already have a prescriber and know you're paying cash? Use NovoCare instead.

When will generic Ozempic be available in the United States?

No reliable U.S. launch date has been established. Apotex's tentative approval and FDA's July 28, 2026 revised product-specific guidance move generic development forward, but final FDA approval, unresolved intellectual-property barriers, manufacturing, a commercial launch decision, distribution, and pharmacy stocking still have to occur. A patent date is not a pharmacy-shelf date. ^{1, 20, 2}

What changed on July 28, 2026

FDA published 17 revised draft product-specific guidances for peptide products. The list included separate guidances for semaglutide referencing Ozempic and semaglutide referencing Wegovy, plus guidances for tirzepatide, liraglutide, and other peptide drugs. ²⁰

FDA said the revisions update recommendations across five areas:

1. Submission of recombinant, synthetic, or semi-synthetic peptides through abbreviated new drug applications
2. Innate immune-response testing
3. Impurity thresholds
4. Higher-order structure assessment
5. Biological-activity assessment ²⁰

That is real progress. It gives developers and FDA reviewers a more current roadmap for generic peptide applications.

It is not approval of a particular generic Ozempic. It does not convert Apotex's tentative approval into final approval. It does not establish a launch date or a pharmacy price.

The separate Ozempic and Wegovy guidances matter

The separate entries confirm the product-specific point running through this page: generic development is tied to a particular reference product. An Ozempic injection application does not automatically create a generic Ozempic tablet or a generic Wegovy product.

The approval pipeline — where the U.S. stands today

Why you will see different years quoted

Patent records can include compound, formulation, use, and device claims. Exclusivities, litigation, settlements, final FDA action, and business decisions can also affect timing. Pulling one date from one patent and calling it the launch year is not verification.

We're not going to give you a countdown. Any page presenting a single patent-expiration year as a guaranteed pharmacy date is showing you a forecast dressed up as a fact.

For the broader patent register, see our GLP-1 patent expiration research. Treat that page as a patent map, not a promise of a launch date.

Should you wait for generic Ozempic? Here's what the verified prices say

Waiting is not a price plan because no verified U.S. launch date or generic price exists. What you can verify today is Novo Nordisk's current official self-pay schedule: $149 to $499, depending on form, dose, and introductory eligibility. NovoCare's own list-price page displays conflicting $1,027.51 and $997.58 figures, so this page does not use list price to forecast a generic price or claim a precise percentage savings. ^{8, 10}

Read that again, because it is the honest answer to the money question.

We tested a more dramatic comparison: applying broad generic-price averages and a Canadian public-payer formula to Ozempic's U.S. list price. It produced dramatic numbers. It also compared a hypothetical generic injection with a starter tablet dose and made a product-level forecast from market-wide averages.

We cut it.

We cannot tell you what a future generic Ozempic will cost or when it will arrive, and neither can any honest page.

What we can show you is the decision in front of you today.

The current wait-or-act decision table

The limits of this price comparison — read them

We'd rather show you the weak spots than have you find them later:

• The 1.5 mg tablet is a starter dose. It is not an ongoing-dose price for most patients and is not intended to lower blood sugar by itself.
• Tablet and injection are not interchangeable shopping formats. The right formulation is a clinical decision.
• The $199 pen offer lasts only for the first two eligible fills. Month three moves to standard pricing.
• Self-pay prices sit outside insurance. They do not build your deductible or out-of-pocket total.
• Manufacturer programs can change. Every price on this page needs monthly re-verification.
• A future generic price is unknowable today. We will not dress an estimate up as a fact.

The conclusion is not “brand Ozempic will definitely be cheaper than a generic.” The conclusion is:

You are not missing a secret generic, and waiting without checking today's legitimate prices, coverage, and treatment alternatives is not a strategy.

Is there a generic Ozempic for weight loss — or are you asking about the wrong drug?

There is no U.S. generic Ozempic for weight loss. Ozempic injection is approved for glycemic control in adults with type 2 diabetes, specified cardiovascular-risk reduction, and specified kidney outcomes in adults with type 2 diabetes and chronic kidney disease. Ozempic tablets are approved for glycemic control and specified cardiovascular-risk reduction in adults with type 2 diabetes. Neither form is approved for chronic weight management. Wegovy is the semaglutide product approved for that purpose, and a future generic referencing Ozempic would not automatically become generic Wegovy. ^{5, 6, 30, 20}

A big share of people asking whether there is a generic Ozempic are really asking a weight-loss question with the wrong brand name attached. That's not a knock on anyone — Ozempic became the household word. But it changes the answer completely.

If weight management is what you are treating:

• Using Ozempic solely for chronic weight management without an approved Ozempic indication is off-label. Coverage and prescribing rules may differ from an on-label weight-management medication.
• Wegovy is the semaglutide product approved for chronic weight management. It has its own dosage forms, label, prices, and generic-development guidance.
• There is no U.S. generic Wegovy for sale. Apotex's tentative Ozempic injection approval does not create one.
• The current Wegovy tablet self-pay price starts at $149. The 4 mg $149 promotion belongs to Wegovy through August 31, 2026 — not Ozempic. ³¹

So the practical answer is not “find a generic Ozempic seller.” It is “compare the treatment paths approved for the goal you are actually treating.”

A lower price does not make a GLP-1 right for you

Ozempic carries a boxed warning because semaglutide caused thyroid C-cell tumors in rodents; it is unknown whether it causes those tumors, including medullary thyroid carcinoma, in humans. Ozempic is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Its label also contains other serious warnings and precautions. Read the current prescribing information and give the clinician your full medical and medication history before choosing a path. ^{5, 6}

If weight loss is your goal, this is the natural decision point. Ro currently offers FDA-approved weight-management options including Wegovy pill, Wegovy pen, Zepbound options, and Foundayo, with medication billed separately from the membership. ²⁶

→ See whether an FDA-approved weight-management path fits with Ro (sponsored affiliate link; opens in a new tab)

Ro Body is $39 for the first month if you are eligible for treatment, then $149 on the monthly plan or as low as $74 a month with annual prepayment. Medication costs extra. The public insurance checker covers Wegovy pen and Zepbound pen, not every pill option. ^{28, 26}

If you have type 2 diabetes and need a prescription or coverage help rather than a weight-management program, use Find My GLP-1 Path to separate diabetes, weight-management, insurance, and cash-pay treatment paths before choosing a provider.

Are any FDA-approved generic GLP-1 drugs available right now?

Yes. FDA has approved generics referencing Byetta, Victoza, and Saxenda, but none is semaglutide or generic Ozempic. Exenatide and liraglutide are different medicines with different dosing schedules, labels, evidence, and substitution records; they are not interchangeable with Ozempic merely because they are in the GLP-1 class. ^{21, 22, 23}

If your real search was “does any FDA-approved generic GLP-1 exist?”, the answer is yes.

FDA notes that approved generics are not always commercially available on or immediately after the approval date, so verify current pharmacy availability instead of assuming an approval record guarantees stock. Teva separately announced that its Saxenda-referencing liraglutide launched in August 2025. ^{25, 24}

The honest catch

Liraglutide is generally dosed once daily, while Ozempic injection is once weekly. Exenatide and liraglutide have their own approved uses, dosing, warnings, and evidence. A lower price or generic label does not make one a substitute for another.

But this cuts both ways. A person who is cost-first and wants an FDA-approved option today has a real question to take to a clinician:

Is an approved older generic appropriate for my diagnosis, goals, medical history, and coverage — or would changing molecules cost me more in fit than it saves in cash?

That is a legitimate conversation. It is not a workaround and it is not generic Ozempic.

What should you ask your pharmacist or prescriber?

Ask for the exact product name, manufacturer, dosage form, strength, FDA approval status, dispensing source, approved use, and total ongoing cost after any introductory period. Do not switch medications or pay for a listing based only on the words “semaglutide,” “generic,” “same as Ozempic,” or a matching lot number.

Save or print this. It takes two minutes and it is the difference between a clear decision and an expensive one.

Five questions for your pharmacist

1. What is the exact manufacturer, NDC, strength, and dosage form of the product you would dispense?
2. Is it a finally FDA-approved brand or generic, tentatively approved, compounded, imported, or unverified?
3. If it is presented as a generic, is the exact product listed in the Orange Book against the relevant Ozempic reference product?
4. Which licensed pharmacy or authorized distributor supplied it, and can you verify that source?
5. What will I pay now, after any introductory fills, and at the dose my prescriber expects me to use?

Five questions for your prescriber

1. Is this approved for my diagnosis, or would this use be off-label?
2. Why this product and form instead of another FDA-approved treatment path for my situation?
3. What monitoring, follow-up, and dose support come with it?
4. Does anything in my medical history, family history, or current medication list make this a poor fit?
5. What is the plan if coverage, price, tolerability, or availability changes?

Before you pay for “generic Ozempic”: the 10-question checklist

• [ ] I know the exact product name
• [ ] I know the manufacturer
• [ ] I know whether it is injection, pen, vial, or tablet
• [ ] I know the exact strength and concentration
• [ ] I checked tentative status separately from final approval
• [ ] I checked the Orange Book for the exact finally approved product
• [ ] I know the licensed dispensing pharmacy or outsourcing facility
• [ ] A valid prescription is required
• [ ] I know the price after every introductory term
• [ ] My clinician or pharmacist has confirmed that the product and treatment path fit my situation

No email required. It is a checklist, not a lead magnet.

What did The RX Index actually verify?

The RX Index checked consequential regulatory claims against FDA and Health Canada, current product and safety claims against FDA labels, and changing commercial terms against the manufacturer or provider publishing them. We did not buy, test, prescribe, or personally use any product discussed here, and we do not claim a medical-review process that did not occur.

We separate three kinds of claims because they need three different kinds of proof.

Regulatory facts — checked against the issuing authority

• FDA's definition of tentative approval and the rule that a tentatively approved product cannot be marketed
• FDA's Orange Book rule excluding tentative approvals and the need to check separate tentative-approval information
• Apotex's April 10, 2026 announcement and the fact that its application covers semaglutide injection
• FDA's current Ozempic injection and tablet labels, including dosage forms, strengths, indications, and boxed warning
• FDA's July 28, 2026 publication of 17 revised draft peptide product-specific guidances and the separate Ozempic and Wegovy entries
• FDA's current compounding policy, marketing restrictions, salt-form warning, dosing concerns, and adverse-event totals
• FDA's three counterfeit Ozempic alert updates through December 5, 2025
• FDA approvals for generic exenatide and liraglutide, plus Teva's announced Saxenda-generic launch
• Health Canada's April 28 and May 1, 2026 generic Ozempic authorizations
• FDA's current personal-importation guidance

Commercial facts — checked at the company publishing the terms on August 4, 2026

• NovoCare Ozempic tablet and pen self-pay prices
• The two-fill $199 new-patient pen offer and its current December 31, 2026 offer deadline
• Ozempic Savings Offer terms and government-program exclusions
• Novo Nordisk Patient Assistance Program eligibility specific to Ozempic in 2026
• NovoCare's conflicting $1,027.51 and $997.58 list-price displays, which is why this page does not publish percentage-savings calculations
• Ro Body membership pricing, medication-separate disclosure, insurance-concierge service, and public coverage-checker scope

Our original analysis — inputs cited and method visible

• The Generic Ozempic Status Board classifies products by country, dosage form, approval stage, and dispensing category
• The Four-Question Headline Test asks which product, form, country, and approval status a claim refers to
• The Two-Check Rule separates tentative status from final Orange Book approval
• The six-question claim checker turns those rules into a product-classification decision tree
• The counterfeit alert table combines three FDA updates into one lot-and-serial record
• The price ladder and list-price mismatch check separate current offer prices from a manufacturer page that displays two different list-price figures
• The wait-or-act table separates what is verifiable now from what no source can promise

What we did not do

We did not buy, test, dispense, or use any medication. We did not inspect a pharmacy, verify a reader's product, diagnose a condition, recommend a dose, or predict a generic launch date or price. We did not use customer testimonials as proof of approval, safety, effectiveness, or equivalence.

What must be rechecked before you act

• Apotex's tentative-versus-final approval status
• Any new Orange Book listing
• NovoCare self-pay and savings terms
• Your own formulary, indication, deductible, and prior-authorization requirements
• FDA's pending 503B bulks-list proposal
• Current counterfeit alerts
• The exact pharmacy and product you are considering

Frequently asked questions about generic Ozempic

These answers close the remaining status, form, cost, country, safety, and timing questions behind “is there a generic Ozempic?” Each answer is U.S.-specific and current through August 4, 2026 unless the question says otherwise.

Is there a generic Ozempic in the U.S. right now?

No. No generic Ozempic can be legally marketed or sold in the United States as of August 4, 2026. Apotex has tentative FDA approval for a semaglutide injection, but tentative approval is not final approval and does not permit sale. ^{1, 2}

Has FDA approved a generic Ozempic?

FDA has granted tentative approval to Apotex's application for a semaglutide injection referencing Ozempic. That is a real review milestone, but it is not final approval and the product cannot be marketed in the U.S. yet. ^{1, 2}

What does FDA tentative approval mean?

It means the application otherwise meets approval requirements, but final approval is blocked by remaining patent, exclusivity, or other issues. Tentatively approved products cannot be marketed and are excluded from the Orange Book until final approval. ^{2, 3}

Is semaglutide the generic version of Ozempic?

Semaglutide is the nonproprietary ingredient name. That word alone does not establish that a finished product is an FDA-approved generic Ozempic; you still need the manufacturer, dosage form, strength, approval record, and dispensing source.

Is there a generic Ozempic pill?

No. Ozempic tablets are branded products in 1.5 mg, 4 mg, and 9 mg strengths. Apotex's tentative approval concerns semaglutide injection, not the tablets. ^{6, 1}

Is compounded semaglutide the same as generic Ozempic?

No. Compounded semaglutide is not FDA-approved as a generic, and FDA does not review the finished compounded drug for safety, effectiveness, or quality before marketing. FDA also bars marketers from calling non-FDA-approved compounded GLP-1 products generic or the same as an approved drug. ^{12, 11}

Can I buy Canadian generic Ozempic for use in the United States?

Canada has authorized generic semaglutide injections referencing Ozempic, but those authorizations are not U.S. FDA approvals. FDA says personal importation of unapproved drugs is illegal in most circumstances and it cannot assure the safety or effectiveness of medicines bought from foreign online sources. ^{17, 18, 19}

Is there a generic Wegovy?

No U.S. generic Wegovy is for sale. FDA's July 2026 guidance treats Wegovy as its own reference product, so a generic application referencing Ozempic does not automatically become generic Wegovy. ²⁰

What is the cheapest published Ozempic price without insurance?

The lowest current official self-pay price is $149 for a 30-day supply of the 1.5 mg Ozempic tablet, which is the starter dose. Ongoing tablet prices are $199 for 4 mg and $299 for 9 mg; standard pen prices are $349 for 0.25, 0.5, or 1 mg and $499 for 2 mg, with a $199 first-two-fill offer for eligible new low-dose pen patients. ⁸

Will a future generic Ozempic be cheaper than current brand self-pay pricing?

No trustworthy source can answer that yet. No U.S. generic has final approval or a launched price, so any exact generic price is a forecast. Compare current official prices and coverage now; compare the actual generic only after it receives final approval and launches.

How do I know an Ozempic pen is not counterfeit?

Use a valid prescription and a state-licensed pharmacy, then check FDA's current alert details. FDA's newest warning involved PAR1229, an authentic lot number also printed on counterfeits, so a matching lot number alone is not enough. ¹⁶

Are any FDA-approved generic GLP-1 drugs available?

Yes. FDA has approved generics referencing Byetta, Victoza, and Saxenda. They contain exenatide or liraglutide, not semaglutide, and none is generic Ozempic. ^{21, 22, 23}

Is Ozempic approved for weight loss?

No. Ozempic injection is approved for glycemic control in adults with type 2 diabetes, specified cardiovascular-risk reduction, and specified kidney outcomes in adults with type 2 diabetes and chronic kidney disease. Ozempic tablets are approved for glycemic control and specified cardiovascular-risk reduction in adults with type 2 diabetes. Neither form is approved for chronic weight management; Wegovy is the semaglutide product approved for that purpose. ^{5, 6, 30}

Not sure which GLP-1 program is right for you?

You came here for a yes or no. The honest answer turned out to be more useful than either: there is no U.S. generic, some of what is marketed as one belongs to a completely different category, and legitimate FDA-approved self-pay paths now start at $149.

Still not sure which GLP-1 program is right for you? Take our free matching quiz.

→ Find My GLP-1 Path

Your result considers your state, insurance, whether you prefer an FDA-approved or compounded treatment path, injection or oral form, and budget. Free, about two minutes. It is informational; a licensed clinician decides what is medically appropriate.

Related guides

• When will GLP-1 generics be available? — the broader timeline across the class
• GLP-1 biosimilar vs. generic explained — the terminology in depth
• Ozempic pill reviews — the tablet form, pricing, routine, and fit
• Does insurance cover Ozempic? — coverage and prior-authorization paths
• Cheapest semaglutide without insurance — current cash-pay routes
• GLP-1 cost calculator — compare medication and program costs
• GLP-1 patent expiration dates — the patent register, without treating a patent date as a launch guarantee
• GLP-1 compounding rules after the shortage — current 503A and 503B distinctions

Sources

1. Apotex receives first U.S. FDA tentative approval for a generic version of Ozempic (semaglutide injection), April 10, 2026

2. FDA Drugs@FDA glossary: tentative approval

3. FDA Orange Book preface

4. FDA Orange Book overview and database

5. FDA prescribing information: Ozempic injection, revised May 2026

6. FDA prescribing information: Rybelsus and Ozempic tablets, revised January 2026

7. Novo Nordisk announcement: Ozempic tablets available in the U.S. beginning May 4, 2026

8. NovoCare diabetes savings and Ozempic self-pay program terms

9. Novo Nordisk Patient Assistance Program

10. NovoCare Ozempic list-price page

11. FDA: enforcement position on marketing non-FDA-approved compounded GLP-1 drugs

12. FDA concerns with unapproved GLP-1 drugs used for weight loss

13. FDA clarification of GLP-1 compounding policies after shortage stabilization

14. FDA proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list

15. FDA human drug compounding policies and rules index

16. FDA counterfeit Ozempic alert

17. Health Canada: first G7 authorization of generic semaglutide, April 28, 2026

18. Health Canada: second generic semaglutide authorization, May 1, 2026

19. FDA personal importation guidance

20. FDA revised draft product-specific guidances for generic peptide products, July 28, 2026

21. FDA 2024 first generic drug approvals

22. FDA approval of the first generic once-daily GLP-1 injection referencing Victoza

23. FDA 2025 first generic drug approvals

24. Teva announcement: FDA approval and U.S. launch of generic Saxenda

25. FDA first generic drug approvals: availability note

26. Ro Body pricing

27. Ro Body insurance and prior-authorization support

28. Ro GLP-1 Insurance Coverage Checker

29. How Ro's weight-management program works

30. FDA prescribing information: Wegovy injection and tablets

31. NovoCare Wegovy self-pay pricing

32. CMS Medicare Prescription Payment Plan

33. NovoCare Medicare cost and Extra Help resources

Provider claims were used only for that provider's own pricing, service, or program details — never as evidence for medical or regulatory claims. Medication choices and substitutions should be discussed with a licensed clinician or pharmacist.

Last verified: August 4, 2026.